Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT05849766

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05849766
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05849766. Randomized; no masking; primary purpose treatment. Start 2023-04-27 (actual); primary completion 2024-05-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
Condition
Dilated Cardiomyopathy
Intervention (Drug)
Dapagliflozin Farxiga®
Intervention (Drug)
Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®
Lead sponsor
October 6 University (class: other)
Collaborator
National Heart Institute, Egypt (class: other government)
Collaborator
University of Florida (class: other)

Record details

Record id
cardio:ct-nct05849766
Content hash
09e183e1728061222600023ca60bd6fac38b0c41e032f441becd423fcfa7d231